Treatment of acute-onset hypertension in pregnancy: A network meta-analysis of randomized controlled trials comparing anti-hypertensives and route of administration.

Adithya D Bhat, Paige M Keasler, Lavanya Kolluru, Michael M Dombrowski, Arvind Palanisamy, Preet Mohinder Singh

Journal: Pregnancy hypertension 2024;34():74-82

PMID: 37857042

Full Text on Elsevier Science View on PubMed

Abstract

BACKGROUND

Consensus on the relative efficacy of available antihypertensive agents used in pregnancy is lacking.

OBJECTIVE

To compare treatment success with antihypertensives and categorize by route of administration.

SEARCH STRATEGY

MEDLINE, Embase, PubMed, Web of Science, Scopus, CINAHL, and clinicaltrials.gov were searched without date restriction.

DATA COLLECTION

Peer-reviewed randomized controlled trials (RCTs) comparing pharmacologic agents used to treat hypertension in parturients were included. Evaluated treatment groups included IV-labetalol (BBIV), IV-hydralazine (DIV), oral-nifedipine (CCBPO), sublingual nifedipine (CCBSL), IV-calcium channel blocker (nonspecific)(CCBIV), IV-nitroglycerine (NTG), epoprostenol infusion (PRO), IV-ketanserin (5HT2B), IV-diazoxide (BZO), oral-nifedipine + methyldopa (CCBAG), oral-methyl-dopa (AAG), and oral prazosin (ABPO).

ANALYSIS

Seventy-four studies (8324 patients) were eligible post PRISMA guidelines screening. Results were pooled using a Bayesian-approach for success of treatment (study defined target blood pressure), time to achieve target pressure, and neonatal intensive-care admissions.

RESULTS

Treatment success (primary outcome, 55 trials with 5518 patients) was analyzed. Surface under the cumulative ranking curve (SUCRA) was categorized for 13 drugs, CCBPO (0.84) followed by CCBSL (0.78) were most likely to be effective in achieving target blood pressure. After sub-grouping by presence/absence of preeclampsia, CCB-PO ranked highest for both [(0.82) vs. (0.77), respectively]. Serotonin antagonists (0.99) and nitroglycerin (0.88) ranked highest for time to target pressure. NICU admissions were lowest for alpha-2 agonists (0.89), followed by BB PO (0.82) and hydralazine IV (0.49).

CONCLUSION

Oral calcium-channel blockers ranked highest for treatment success. Ketanserin achieved target blood pressure fastest, warranting additional research. The results should be interpreted with caution as SUCRA values may not indicate whether the differences between interventions have clinically meaningful effect sizes.

Address: Department of Anesthesiology, Washington University School of Medicine in St. Louis, MO, USA.; Department of Anesthesiology, Washington University School of Medicine in St. Louis, MO, USA; Department of Anesthesiology, University of Washington Medical Center, WA, USA.; University of Missouri-Kansas City School of Medicine, MO, USA.; Department of Obstetrics and Gynecology, Washington University School of Medicine in St. Louis, MO, USA.; Department of Anesthesiology, Washington University School of Medicine in St. Louis, MO, USA. Electronic address: [email protected].

DOI: 10.1016/j.preghy.2023.10.005

Link outs

Free resources

Medical:

https://medlineplus.gov/highbloodpressure.html

Subscription / membership required

Full Text Sources:

MeSH Terms: Female, Humans, Infant, Newborn, Pregnancy, Antihypertensive Agents, Calcium Channel Blockers, Hydralazine, Hypertension, Ketanserin, Methyldopa, Nifedipine, Pre-Eclampsia, Randomized Controlled Trials as Topic